CORRESP 1 filename1.htm

 

 

September 12, 2024

 

 

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F. Street, NE

Washington, D.C. 20549

Attention: Jane Park

 

 

Re:   NeuroOne Medical Technologies Corporation
 Registration Statement on Form S-3
 File No. 333-281881
 

Acceleration Request

  
                 Requested Date:  September 13, 2024
                 Requested Time:  4:30 P.M. Eastern Time

 

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, NeuroOne Medical Technologies Corporation (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-281881) (as amended, the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Emily J. Johns and Lauren Legner of Honigman LLP, counsel to the Company, to make such request on its behalf.

 

Please confirm the effectiveness of the Registration Statement with Emily J. Johns of Honigman LLP by telephone at (616) 649-1908 or Lauren Legner of Honigman LLP by telephone at (313) 465-7119.

 

[Signature page follows]

 

****

 

 

 

 

 

  Sincerely,
   
  NeuroOne Medical Technologies corporation
   
  /s/ David Rosa
  David Rosa
Chief Executive Officer

 

cc:Emily J. Johns, Honigman LLP
  Lauren Legner, Honigman LLP